201
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Knuckle Pads Successfully Treated with 2% Crisaborole Ointment Combined with Triamcinolone Acetonide and Neomycin Plaster: A Case Report

, , ORCID Icon, ORCID Icon, , & show all
Pages 1893-1897 | Received 20 Apr 2023, Accepted 16 Jun 2023, Published online: 24 Jul 2023

References

  • Tamborrini G, Gengenbacher M, Bianchi S. Knuckle pads - a rare finding. J Ultrason. 2012;12(51):493–498. doi:10.15557/JoU.2012.0037
  • Sogliani D, Mura C, Tamborrini G. Successful treatment of idiopathic knuckle pads with a combination of high-dose salicylic acid and urea topical keratolytics: a case report. Dermatol Rep. 2021;13(1):9072. doi:10.4081/dr.2021.9072
  • De Keersmaeker A, Vanhoenacker F. Imaging features of knuckle pads. J Belg Soc Radiol. 2016;100(1):67. doi:10.5334/jbr-btr.1096
  • Luber AJ, Bienenfeld AR, Clark CM, et al. Characterization of knuckle (Garrod) pads using optical coherence tomography in vivo. Cutis. 2015;96(3):E10–1.
  • Paller AS, Hebert AA. Knuckle pads in children. Am J Dis Child. 1986;140(9):915–917. doi:10.1001/archpedi.1986.02140230085039
  • Caroli A, Zanasi S, Marcuzzi A, et al. Epidemiological and structural findings supporting the fibromatous origin of dorsal knuckle pads. J Hand Surg Br. 1991;16(3):258–262. doi:10.1016/0266-7681(91)90049-t
  • Herold M, Russe‐Wilflingseder K. Knuckle pads—a common problem but good to treat by laser. AIP Conf Proc. 2010;1226(1):179–183. doi:10.1063/1.3453778
  • Weiss E, Amini S. A novel treatment for knuckle pads with intralesional Fluorouracil. Arch Dermatol. 2007;143(11):1458–1460. doi:10.1001/archderm.143.11.1458
  • Hasbún C, Sandoval M, Curi M. A novel treatment for idiopathic knuckle pads with cantharidin-podophylotoxin-salicylic acid. Pediatr Dermatol. 2019;36(4):544–545. doi:10.1111/pde.13803
  • Sławińska M, Nowicki RJ, Sobjanek M. Silicone gel sheets in treatment of pseudo-knuckle pads: a case report. Dermatol Ther. 2022;35(4):e15325. doi:10.1111/dth.15325
  • Hoy SM. Crisaborole ointment 2%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2017;18(6):837–843. doi:10.1007/s40257-017-0327-4
  • Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494–503.e6. doi:10.1016/j.jaad.2016.05.046
  • Makins C, Sanghera R, Grewal PS. Off-label therapeutic potential of crisaborole. J Cutan Med Surg. 2020;24(3):292–296. doi:10.1177/1203475420909794
  • Wei G, Rodriguez-Waitkus P, Soylu L. A rare case of lichen simplex chronicus in an adolescent female successfully managed with Crisaborole. Dermatol Ther. 2021;34(2):e14752. doi:10.1111/dth.14752
  • Nakajima K, Nakajima R, Morisaka H, et al. Beneficial impact of apremilast on palmoplantar keratodermas. Acta Derm Venereol. 2021;101(4):adv00437. doi:10.2340/00015555-3805
  • Kohyama T, Liu X, Wen FQ, et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol. 2002;26(6):694–701. doi:10.1165/ajrcmb.26.6.4743
  • Pellanda C, Strub C, Figueiredo V, et al. Topical bioavailability of triamcinolone acetonide: effect of occlusion. Skin Pharmacol Physiol. 2007;20(1):50–56. doi:10.1159/000096172
  • Ly S, Amici JM. Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review. Drugs Context. 2018;7:212539. doi:10.7573/dic.212539